Skip to main content
. 2020 Dec 10:NEJMoa2034577. doi: 10.1056/NEJMoa2034577

Figure 1. Enrollment and Randomization.

Figure 1

The diagram represents all enrolled participants through November 14, 2020. The safety subset (those with a median of 2 months of follow-up, in accordance with application requirements for Emergency Use Authorization) is based on an October 9, 2020, data cut-off date. The further procedures that one participant in the placebo group declined after dose 2 (lower right corner of the diagram) were those involving collection of blood and nasal swab samples.